385 reports of this reaction
1.5% of all EPLERENONE reports
#16 most reported adverse reaction
HYPERKALAEMIA is the #16 most commonly reported adverse reaction for EPLERENONE, manufactured by Viatris Specialty LLC. There are 385 FDA adverse event reports linking EPLERENONE to HYPERKALAEMIA. This represents approximately 1.5% of all 25,060 adverse event reports for this drug.
Patients taking EPLERENONE who experience hyperkalaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERKALAEMIA is a less commonly reported adverse event for EPLERENONE, but still significant enough to appear in the safety profile.
In addition to hyperkalaemia, the following adverse reactions have been reported for EPLERENONE:
The following drugs have also been linked to hyperkalaemia in FDA adverse event reports:
HYPERKALAEMIA has been reported as an adverse event in 385 FDA reports for EPLERENONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERKALAEMIA accounts for approximately 1.5% of all adverse event reports for EPLERENONE, making it a notable side effect.
If you experience hyperkalaemia while taking EPLERENONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.